2026-06-14T03:31:05Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/142952025-05-05T12:43:40Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_19609col_20.500.12105_16938col_20.500.12105_16963col_20.500.12105_16974col_20.500.12105_16978col_20.500.12105_16979col_20.500.12105_16988

00925njm 22002777a 4500 dc Berenguer, Juan author Díez, Cristina author Martin-Vicente, Maria author Micán, Rafael author Pérez-Elías, María-Jesús author García-Fraile, Lucio Jesús author Vidal, Francisco author Suárez-García, Inés author Podzamczer, Daniel author Del Romero, Jorge author Pulido, Federico author Iribarren, José Antonio author Gutiérrez, Félix author Poveda, Eva author Galera, Carlos author Izquierdo Miguel, Rebeca author Asensi, Víctor author Portilla, Joaquín author López, Juan C author Arribas, José R author Moreno, Santiago author González-García, Juan author Resino, Salvador author Jarrin Vera, Inmaculada author 2021-11 Objectives: We aimed to assess the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and factors associated with seropositivity and asymptomatic coronavirus disease 2019 (COVID-19) among people with HIV (PWH). Methods: This was a cross-sectional study carried out within the cohort of the Spanish HIV Research Network. Participants were consecutive PWH with plasma collected from 1st April to 30th September 2020. We determined SARS-CoV-2 antibodies (Abs) in plasma. Illness severity (NIH criteria) was assessed by a review of medical records and, if needed, participant interviews. Multivariable logistic regression analysis was used to identify predictors of seropositivity among the following variables: sex, age, country of birth, education level, comorbidities (hypertension, chronic heart disease, diabetes mellitus, non AIDS-related cancer, chronic kidney disease, cirrhosis), route of HIV acquisition, prior AIDS, CD4þ cell count, HIV viral load, nucleoside/nucleotide reverse transcriptase inhibitor (N [t]RTI) backbone, type of third antiretroviral drug, and month of sample collection. Results: Of 1076 PWH (88.0% males, median age 43 years, 97.7% on antiretroviral therapy, median CD4þ 688 cells/mm3 , 91.4% undetectable HIV viral load), SARS-CoV-2 Abs were detected in 91 PWH, a sero prevalence of 8.5% (95%CI 6.9e10.3%). Forty-five infections (45.0%) were asymptomatic. Variables inde pendently associated with SARS-CoV-2 seropositivity were birth in Latin American countries versus Spain (adjusted odds ratio (aOR) 2.30, 95%CI 1.41e3.76, p 0.001), and therapy with tenofovir disoproxil fumarate plus emtricitabine (TDF/FTC) versus tenofovir alafenamide (TAF)/FTC as the N(t)RTI backbone (aOR 0.49, 95%CI 0.26e0.94, p 0.031). Conclusions: Many SARS-CoV-2 infections among PWH were asymptomatic, and birth in Latin American countries increased the risk of SARS-CoV-2 seropositivity. Our analysis, adjusted by comorbidities and other variables, suggests that TDF/FTC may prevent SARS-CoV-2 infection among PWH. Clin Microbiol Infect. 2021 Nov;27(11):1678-1684. 10.1016/j.cmi.2021.06.023 1469-0691 Clinical Microbiology and Infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases 34186209 http://hdl.handle.net/20.500.12105/14295 COVID-19 HIV SARS-CoV-2 Serology Seroprevalence Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort